| Theme |
Autoimmune Pancreatitis |
| Title |
Long-term Outcome for Autoimmune Pancreatitis |
| Author |
Hisato Igarashi |
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University |
| Author |
Tetsuhide Ito |
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University |
| Author |
Takamasa Oono |
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University |
| Author |
Mikihiko Yasuda |
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University |
| Author |
Taichi Nakamura |
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University |
| Author |
Nao Fujimori |
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University |
| Author |
Yuhsuke Niina |
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University |
| Author |
Masahiko Uchida |
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University |
| Author |
Ryoichi Takayanagi |
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University |
| [ Summary ] |
Autoimmune pancreatitis (AIP) can be defined as a chronic inflammation of the pancreas owing to an autoimmune mechanism. Natural histories and long-term outcomes have been obscure. However, recent studies of AIP have revealed a great deal of new information concerning these factors. Although oral steroidal therapy is effective for treating AIP, cases of relapse have been reported after or during steroid therapy and natural remission cases without steroids have also been observed. The long-term outcome, suggests that some patients exhibit pancreatic atrophy, while others develop pancreatic stones. AIP patients frequently express dysfunction of pancreatic, endocrine and/or exocrine function. Some patients experience functional recovery after steroidal therapy. However, with longterm follow up, some patients exhibit further reductions in pancreatic complications. Recently, there have been reports of AIP developing into pancreatic cancer after steroidal therapy. However, it is rarely observed during initial diagnosis. Further investigation will be required concerning long-term outcomes for AIP. |